Securities Star News, Kehua Bio (002022) answered investors’ concerns on the investor relations platform on August 29th.For the immediate pressure, 喵喵出海 With its own coping style, it can break the predicament and usher in a new life through the quality of the product itself. https://www.mailpowering.com
Investor: Hello, Secretary Dong! (On August 16th, it was indicated on the investor interaction platform that the monkey pox nucleic acid detection reagent of Tianlong Company, the holding subsidiary of the company, based on the fluorescent PCR technology platform has obtained the registration certification of EU CE and UK MHRA, and the product has been applied to some domestic provincial and municipal centers for disease control and customs inspection, and exported to many overseas countries simultaneously. ) This is the monkey pox nucleic acid detection reagent announced by the company. Now there is a suspected monkey pox epidemic in Thailand, and your company also has a subsidiary in Thailand. Have you purchased reagents from your company in Thailand? thank you
Kehua Bio-Secretary: Dear investors, hello! The company actively explores the international market and deploys local service teams overseas, but it has not yet set up a subsidiary in Thailand. At present, the monkey pox nucleic acid detection reagent products of Tianlong Company, a holding subsidiary of the company, have not been exported to Thailand. Thank you for your attention!
The above contents are compiled by Securities Star according to public information and generated by intelligent algorithm, which does not constitute investment advice.